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Abstract
Background: Although previous studies showed an increasing prevalence of infections due to multi-drug resistant
(MDR) bacteria in the community, specific data on sepsis are lacking. We aimed to assess prevalence, risk factors
and outcomes of patients with sepsis due to MDR bacteria.
Methods: An observational, retrospective study was conducted on consecutive adult patients coming from the
community and admitted to the Policlinico Hospital, Milan, Italy, with a diagnosis of sepsis between January 2011
and December 2015. Primary study outcome was in-hospital mortality.
Results: Among 518 patients, at least one MDR bacteria was isolated in 88 (17%). ESBL+ Enterobacteriaceae were the
most prevalent MDR bacteria (9.7%) followed by MRSA (3.9%). Independent risk factors for sepsis due to MDR bacteria
were septic shock (OR: 2.2; p = 0.002) and hospitalization in the previous 90 days (OR: 2.3; p = 0.003). Independent risk
factors for sepsis due to ESBL+ bacteria were hospitalization in the previous 90 days (OR: 2.1; p = 0.02) and stroke
(OR: 2.1; p = 0.04). A significantly higher mortality was detected among patients with vs. without MDR bacteria (40.2%
vs. 23.1% respectively, p = 0.001). Independent risk factors for mortality among patients with sepsis were coagulation
dysfunction (OR: 3.2; p = 0.03), septic shock (OR: 3.2; p = 0.003), and isolation of a MDR bacteria (OR: 4.6; p < 0.001).
Conclusion: In light of the prevalence and impact of MDR bacteria causing sepsis in patients coming from the
community, physicians should consider ESBL coverage when starting an empiric antibiotic therapy in patients with
specific risk factors, especially in the presence of septic shock.
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Summary
Specific risk factors for MDR bacteria and EBSL+ Entero-
bacteriaceae are found in a population of 518 patients with
sepsis coming from the community. Isolation of a MDR
bacteria is associated with higher mortality rates and is an
independent risk factor for mortality.
Introduction
Sepsis is a major health-care problem which affects mil-
lions of people each year worldwide with an increasing
incidence over the last decades [1]. More than one
third of patients with sepsis die during their hospital
stay and the economic impact of sepsis is relevant, with
a mean and median hospital and intensive care unit
(ICU) cost of $32,421 and $27,461 per single patient,
respectively [2, 3]. Recently, a new definition of sepsis
and an update of the Surviving Sepsis Campaign guide-
lines have been published to improve sepsis diagnosis,
to standardize communication between clinicians and
researchers, and to spread an evidence based approach
for the management of septic patients [1, 4].
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These guidelines confirm the appropriateness of initial
antibiotic therapy as a crucial variable in septic patients [1,
5–9]. Among the major contributors of the increasing rates
of inappropriate empiric antimicrobial treatment, the
spread of antimicrobial resistance seems to be one of the
most relevant [5, 6]. An update on sepsis epidemiology
due to multi-drug resistant organisms (MDRO) and on its
associated risk factors would be very helpful for clinicians
to early detect patients requiring a broader antibiotic
coverage.
Several experiences reported on risk factors for
MDRO infections, enrolling heterogeneous patient
populations. Some of them considered infections due to
specific MDRO, mainly methicillin-resistant Staphylo-
coccus aureus (MRSA) and extended-spectrum
beta-lactamase (ESBL) producing Enterobacteriaceae
[10–15], while others included patients with infection
limited to one organ, such as pneumonia and urinary
tract infections [16–20]. Finally, few other studies have
been published on the impact of bacterial resistances in
bloodstream infections, regardless the presence of sep-
sis [21–23]. No previous studies specifically evaluated
prevalence, characteristics, and risk factors for MDRO
in a specific sample of patients with sepsis.
The aim of this study was to assess prevalence, charac-
teristics, risk factors, and outcomes of patients suffering
of sepsis due to MDRO.
Materials and methods
Study design and study patients
This was an observational, retrospective study enrolling
consecutive adult patients coming from the community
and admitted to the Emergency Department (ED) of the
IRCCS Fondazione Ca′ Granda, Ospedale Maggiore Poli-
clinico of Milan, Italy, with sepsis between January 2011
and December 2015. Patients ≥18 years of age fitting sep-
sis criteria were included [4]. Patients admitted to the ED
of the Policlinico Hospital coming from other hospitals
were excluded. The study was approved by the ethical
committee (262_2017bis) of the IRCCS Fondazione Ca′
Granda, Ospedale Maggiore Policlinico of Milan, Italy,
whereas informed consent was waived due to the retro-
spective and observational nature of the study according
to the Italian law on observational studies.
Data collection
Demographics, comorbidities, risk factors for MDRO,
Charlson Comorbidity Index, clinical, laboratory and
microbiological findings on admission, site of infection,
disease severity (organ dysfunction, septic shock, SOFA
score) empiric antibiotic therapy, vasopressor use and in-
vasive mechanical ventilation data were recorded [24, 25].
Risk factors for MDRO
The following risk factors for MDRO were recorded:
nursing home or extended care facility residency,
hospitalization for ≥2 days in the preceding 90 days, anti-
microbial therapy in the preceding 90 days, home infu-
sion therapy (including antibiotics), home wound care,
indwelling bladder catheter, indwelling intravascular de-
vices, chronic renal failure, chronic dialysis at least dur-
ing the prior 30 days, day hospital attendance for
infusion therapy or blood transfusions, mild, moderate
and severe immunodepression [26].
Study outcomes and definitions
The primary study outcome was in-hospital mortality. Sec-
ondary study outcome was length of hospital stay (LOS).
Sepsis and septic shock were defined according to the
Third International Consensus Definitions for Sepsis and
Septic Shock [4]. Sepsis was defined as life-threatening
organ dysfunction caused by a dysregulated host response
to infection. Organ dysfunction was identified as an acute
change in total SOFA score ≥ 2 points following the infec-
tion. Septic shock was defined as a subset of sepsis in
which underlying circulatory and cellular metabolism ab-
normalities are severe enough to increase significantly
mortality. This condition was identified with a clinical
construct of sepsis with persisting hypotension requiring
vasopressors to maintain mean arterial pressure (MAP)
≥65mmHg and having a serum lactate level > 2mmol/L
(18mg/dL) despite adequate volume resuscitation.
Severe immunodepression was defined by the presence
of at least one of the following medical conditions: active
hematologic malignancy, transplantation, immunosup-
pressive therapy, chemotherapy and radiotherapy in the
30 days before the ED admission. Mild-to-moderate
immunodepression was defined by the presence of at least
one of the following medical conditions: chronic systemic
steroid therapy (prednisone ≥25mg daily), active solid ma-
lignancy, splenectomy, and autoimmune disease.
In-hospital mortality was defined as all-cause mortality
occurring during hospitalization. LOS was calculated as
the number of days from the date of hospital admission
to the date of discharge.
Microbiological data and empiric antibiotic therapy
Microbiological results performed within 48 h since hos-
pital admission were recorded, including blood, sputum,
tracheobronchial aspirate, urine, wound, and mucosal
swab cultures, as well as Legionella pneumophila and
Streptococcus pneumoniae urinary antigens. Species
identification and antimicrobial susceptibility testing
were performed using an automated system (Vitek 2®;
BioMérieux); susceptibility break-points were based on
Anti-microbial Susceptibility Testing (EUCAST) guidelines.
[EUCAST breakpoint table version 1.2 to table version 5.0].
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MRSA, Pseudomonas aeruginosa resistant to three clas-
ses of antibiotics among antipseudomonal penicillins, anti-
pseudomonal cephalosporins, carbapenems, quinolones,
and aminoglycosides, vancomycin-resistant Enterococcus,
Acinetobacter baumanii, ESBL producing Enterobacteria-
ceae, carbapenemase-producing Klebsiella pneumoniae,
and other pathogens with acquired non-susceptibility to at
least one agent in three or more antimicrobials categories
were considered as MDR bacteria [27].
Empiric antibiotic therapy administered in the ED
after diagnosis of sepsis and septic shock was recorded,
together with its appropriateness according to the anti-
biotic susceptibility of the isolated pathogen and the
agreement with local guideline (see Additional file 1:
Table S1).
Statistical analysis
An ad hoc electronic form was used to collect all demo-
graphic, epidemiological, clinical, and microbiological var-
iables. Qualitative and quantitative data were summarized
with absolute and relative (percentage) frequencies and
medians (interquartile ranges, IQR) according to their
non-parametric distribution, respectively. Statistical differ-
ences of qualitative and quantitative variables were
assessed with chi-squared or Fisher exact, when appropri-
ate, and Mann-Whitney tests, respectively. Logistic regres-
sion analyses were carried out to assess the relationship
between MDRO or ESBL+ infection and the collected co-
variates. A two-tailed p less than 0.05 was considered sta-
tistically significant. The statistical software STATA 14
(StataCorp LP, Lakeway Drive, College Station, USA) was
used to perform all statistical computations.
Results
Study population
A total of 663 consecutive patients with sepsis were en-
rolled during the study period (56.6% males, median [IQR]
age: 80 [71–87] years). The final study population consisted
of 518 patients (78.1% of the total enrolled) who underwent
at least one bacteriological test within the first 24 h after
hospitalization.
Demographics, comorbidities, risk factors for MDRO,
clinical, and laboratory findings on admission, site of infec-
tion, disease severity, therapy prescribed within 24 h after
admission are summarized in Table 1: lung (59.9%) and
urinary tract (36.4%) were the most common sites of infec-
tion. A total of 146 (28.2%) patients had septic shock.
Three hundred ninety-seven patients (76.6%) had at
least one risk factor for MDRO: hospitalization in the pre-
vious 3months (28.4%), day hospital attendance (19.3%),
severe immunodepression (18.9%), and antibiotic therapy
in the last 90 days (15.5%) were the most frequent risk fac-
tors for MDRO.
Prevalence and characteristics of patients with sepsis due
to MDRO and ESBL+ bacteria
Cultures were performed on blood (n = 446, 86.1%) and
sputum (n = 25, 4.8%) samples, tracheobronchial aspirates
(n = 27, 5.2%), urine (n = 189, 36%] and other (n = 47,
9.1%) samples. Microbiological findings are summarized
in Table 2. At least one pathogen was isolated in 305 pa-
tients (58.9%) and, among them, 198 (44.5%) had
bacteremia.
At least one MDRO was isolated in 88 patients (17%
among the entire population and 29.1% among culture
positive patients), with ESBL+ Enterobacteriaceae being
the most prevalent isolates (50 patients, 9.7%), including
43 (8.3%) patients with ESBL+ E. coli and 7 (1.4%) with
ESBL+ K. pneumoniae. The second most prevalent
MDR bacteria were MRSA (20 patients, 3.9%).
Demographics, comorbidities, risk factors, clinical and
laboratory findings on admission, site of infection, disease
severity, appropriateness of empiric antibiotic therapy,
vasopressor use and invasive mechanical ventilation of the
study sample are reported in the online supplement ac-
cording to the presence of MDRO (Additional file 1: Table
S2) and ESBL+ bacteria (Additional file 1: Table S3).
Independent risk factors associated to MDRO and ESBL+
infection in patients with sepsis
After adjusting for several confounders, independent risk
factors associated with the occurrence of sepsis due to
MDRO and ESBL+ bacteria are reported in Tables 3 and 4.
Significant independent risk factors for sepsis due to
MDRO were septic shock (OR: 2.2; 95% CI: 1.3–3.7, p =
0.002) and hospitalization in the past 90 days (OR: 2.3; 95%
CI: 1.3–4.1, p = 0.003). Significant independent risk factors
for sepsis due to ESBL+ bacteria were hospitalization in the
past 90 days (OR: 2.1; 95% CI: 1.2–3.9, p = 0.02) and stroke
(OR: 2.1; 95% CI: 1.0–4.1, p = 0.04).
Study outcomes
In-hospital mortality was 25.7% (n = 133). Among pa-
tients with septic shock 69 (47.3%) died. Demographics,
comorbidities, risk factors, clinical laboratory, and
microbiological findings on admission, site of infection,
disease severity, appropriateness of empiric antibiotic
therapy, vasopressors use and invasive mechanical venti-
lation of patients who died versus those who survived
are summarized in Table 5.
The median (IQR) LOS was 13 (8–21) days. Among
patients with MDRO the median (IQR) LOS was 15 (9–
22) days and in-hospital mortality was 40.2% (35 pa-
tients), while among those without MDRO infection
LOS was 13 (8–21) days (p = 0.36) and mortality was
23.1% (n = 98) (p = 0.001).
Among patients with ESBL+ infection the median (IQR)
LOS was 15 (9–21) days and in-hospital mortality was
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Table 1 Study population. (518)
Demographics characteristics
Female, n (%) 220 (42.5)
Median (IQR) age, years 80 (71–87)
Comorbidities, n (%)
Median (IQR) Charlson comorbidity index 6 (5–8)
Hypertension 289 (55.8)
Diabetes mellitus 124 (23.9)
Ischemic heart disease 109 (21.0)
COPD 114 (22.0)
Stroke 83 (16.0)
Dementia 79 (15.3)
Chronic heart failure 50 (9.7)
Chronic liver disease 38 (7.3)
Peripheral vascular disease 28 (5.4)
Hemiplegia 21 (4.1)
Cirrhosis 25 (4.8)
Risk factors for MDR pathogens, n (%)
Patients with at least one risk factor for
MDR pathogens
397 (76.6)
Hospitalization in the past 90 days 147 (28.4)
Median (IQR) LOS 13 (8–21)
Day hospital attendance in the past 90 days 100 (19.3)
Antibiotic therapy in the past 90 days 80 (15.5)
Severe immunosuppression 98 (18.9)
Mild /moderate immunosuppression 83 (16.0)
Solid cancer 73 (14.1)
Chronic steroid therapy 68 (13.1)
Haematological malignancy 45 (8.7)
Chemotherapy 28 (5.4)
AIDS 3 (0.6)
Chronic renal failure 96 (18.5)
Dialysis 16 (3.1)
Home wound care/infusion therapy 82 (15.8)
Indwelling bladder catheter 70 (13.5)
Nursing home or LTCF residency 45 (8.7)
Indwelling intravascular catheters 31 (6.0)
Clinical findings
Median (IQR) body temperature, °C 38.0 (37.1–38.7)
Median (IQR) systolic blood pressure, mmHg 110 (90–135)
Median (IQR) diastolic blood pressure, mmHg 60 (50–70)
Median (IQR) mean blood pressure, mmHg 77 (63–92)
Median (IQR) heart rate, bpm 102 (88–120)
Median (IQR) oxygen saturation, % 95 (91–97)
Median (IQR) respiratory rate, bpm 22 (18–30)
Median (IQR) shock index 0.9 (0.7–1.2)
Table 1 Study population. (518) (Continued)
Laboratory findings
Median (IQR) arterial pH 7.5 (7.4–7.5)
Median (IQR) PaCO2, mmHg 30 (25–35)
Median (IQR) PaO2, mmHg 65 (55–77)
Median (IQR) HCO3
− mEq/L 21.8 (18.0–24.6)
Median (IQR) PaO2/FiO2 ratio 276 (229–333)
Median (IQR) lactate, mEq/L 2.9 (2.1–4.3)
Median (IQR) white blood cells, cell/L−1 12.1 (7.3–17.9)
Median (IQR) platelets, cell/L−1 190.0 (131.0–258.5)
Mean (SD) haemoglobin, g/dL 12.3 (2.3)
Median (IQR) glucose, mg/dL 141 (110–192)
Median (IQR) urea, mg/dL 65 (46–97)
Median (IQR) creatinine, mg/dL 1.6 (1.2–2.4)
Median (IQR) C-reactive protein, g/dL 11.4 (4.5–22.7)
Median (IQR) aspartate aminotransferase U/l 28 (20–50)
Median (IQR) alanine aminotransferase U/l 21 (13–39)
Median (IQR) lactate dehydrogenase 327 (222–457)
Median (IQR) total bilirubin, mg/dL 0.8 (0.5–1.6)
Median (IQR) INR 1.3 (1.2–1.5)
Site of primary infection, n (%)
Lung 273 (59.9)
Urinary tract 166 (36.4)
Abdomen 59 (12.9)
Skin and soft tissue 31 (6.8)
Central nervous system 9 (2.0)
Bone and joints 4 (0.9)
More than one site 82 (15.8)
Unknown origin 62 (12.0)
MOF, n (%)
Metabolic dysfunction 359 (75.6)
Renal failure 223 (43.6)
Hemodynamic failure 200 (39.0)
Cognitive impairment 158 (32.9)
Shock 146 (28.2)
Respiratory failure 94 (18.4)
Liver failure 67 (13.9)
Coagulation dysfunction 56 (12.1)
Haematological dysfunction 51 (9.9)
Antibiotics, n (%)
Azithromycin 40 (5.5)
Piperacillin/Tazobactam 188 (25.9)
Ceftriaxone 164 (22.6)
Levofloxacin 111 (15.3)
Imipenem 66 (9.1)
Vancomycin 51 (7.0)
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32% (n = 16), whereas among those without ESBL+ infec-
tion median (IQR) LOS was 13 (8–22) days (p = 0.73) and
in-hospital mortality was 25.3% (n = 117) (p = 0.27).
Risk factors for mortality in patients with sepsis
After adjusting for several confounders, including anti-
biotic therapy, vasopressor exposure and ventilatory
treatment, independent risk factors associated with
in-hospital mortality in patients with sepsis were: coagu-
lation dysfunction (OR: 3.2; 95% CI: 1.1–8.8, p = 0.03),
septic shock (OR: 3.2; 95% CI: 1.5–7.0, p = 0.003), and
isolation of a MDR pathogen (OR: 4.6; 95% CI: 2.0–10.6,
p < 0.001) (Table 6).
Discussion
The present study shows that more than three quarters of
patients admitted to the hospital from the community for
sepsis have at least one risk factor for MDRO, while in
17% of patients a MDRO is isolated. Among those, ESBL+
Enterobacteriaceae are the most prevalent ones (9.7%).
Hospitalization in the previous 90 days and the presence
of septic shock are the two independent risk factors asso-
ciated with MDRO in patients with sepsis, whereas
hospitalization in the previous 90 days and stroke are in-
dependently associated with infection caused by ESBL
producer Enterobacteraceae.
Our study is in line with previously published data in
terms of frequency of different sites of infection (lung be-
ing the first followed by urinary tract), most frequent or-
gans involved in multi-organ failure, percentage of patients
with septic shock and mortality rate [28, 29]. The
prevalence of MDRO in our study is slightly higher
than those previously reported in literature, mainly
because of the characteristics of our study sample
characterized by elderly patients with several comorbidi-
ties and a long history of medicalization [5, 30, 31]. We
found a discrepancy between the frequency of risk factors
for MDRO and the prevalence of cultures positive for
MDRO. We could speculate that not all risk factors
for MDRO should be equally weighted and share the
same impact on guiding empiric antibiotic therapy in
sepsis.
Table 2 Microbiological findings
Microbiological, n (%)
Patients with isolated microorganism 305 (58.9)
Patients with at least one MDR organism 88 (17.0)
Patients with at least one ESBL organism 50 (9.7)
E. coli ESBL + 43 (8.3)
Methicillin-resistant S. aureus 20 (3.9)
Proteus spp MDR + 5 (1)
K. pneumoniae ESBL + 7 (1.4)
K. pneumomiae carbapenemase producer 6 (1.2)
P. aeruginosa MDR+ 4 (0.8)
Enterococcus spp MDR+ 2 (0.4)
Enterobacter spp MDR + 2 (0.4)
Stenotrophomonas maltophilia MDR+ 1 (0.2)
E. coli ESBL - 77 (14.9)
Methicillin-sensible S. aureus 24 (4.6)
S. pneumoniae 24 (4.6)
K. pneumoniae ESBL- 17 (3.3)
P. aeruginosa MDR- 25 (4.8)
Candida spp 12 (2.3)
Enterococcus spp MDR- 10 (1.9)
Proteus spp MDR-) 9 (1.7)
Enterobacter spp MDR- 5 (1)
N. meningitides 3 (0.6)
Bacteroides spp 1 (0.2)
Providencia spp 2 (0.4)
Stenotrophomonas maltophilia MDR- 3 (0.6)
C. difficile 4 (0.8)
Aspergillus spp 2 (0.4)
Acinetobacter baumanii 1 (0.2)
Salmonella group B 2 (0.4)
H. influenzae 1 (0.2)
Acinetobacter iwoffii 1 (0.2)
Propiniobacterium 1 (0.2)
Serratia spp 2 (0.4)
Polymicrobial infection 29 (5.6)
n number, ESBL extended spectrum beta lactamase, MDR multi-drug resistant,
spp species
Table 1 Study population. (518) (Continued)
Ciprofloxacin 28 (3.9)
Amoxicillin/Clavulanate 22 (3.0)
Metronidazole 16 (2.2)
Meropenem 5 (0.7)
Ampicillin 7 (1.0)
Amikacin 7 (1.0)
Ceftazidime 5 (0.7)
Others 16 (2.2)
Appropriate empiric antibiotic therapy according to
local guidelines
273 (58.3)
Appropriate empiric antibiotic therapy according to
antibiotic susceptibility of the isolated pathogen
155 (66.8)
Use of vasopressors 84 (16.2)
Mechanical ventilation 8 (2.5)
n number, IQR interquartile range, COPD chronic obstructive pulmonary
disease, AIDS Acquired immune deficiency syndrome; LTCF long term care
facility, INR International normalized ratio; MOF: multi organ failure (other than
primary site of infection)
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Among healthcare-related risk factors, hospitalization
in the previous 90 days is the strongest independent vari-
able associated with MDRO-related sepsis. The increas-
ing prevalence of MDRO within the hospital wards, due
to an extensive antibiotic use and transmission between
healthcare workers and patients, might explain this find-
ing, as previously suggested in published manuscripts
[15, 19, 21, 26, 32]. Also, septic shock is a risk factor for
sepsis caused by MDRO, although some could argue
that septic shock is a marker of disease severity and
should not be considered a risk factor itself. As previ-
ously reported, markers of disease severity were included
as risk factors for MDRO mainly because of the impact
that this finding might have in the clinical management.
Our finding on septic shock as independent risk factor
for MDRO clearly identifies a subgroup of more fragile
patients who might deserve a broad-spectrum empiric
antibiotic course based on their disease severity and risk
of organ failure. In light of the high prevalence of
MDRO we found and the high mortality rate of patients
with septic shock, an antibiotic prescription for MDRO
should be considered in shocked patients, especially if
additional risk factors (e.g., previous hospitalization) are
concomitant.
Among all MDRO, ESBL producer Enterobacteriaceae
seems to be the most prevalent (9.7%), with ESBL pro-
ducing E. coli and K. pneumoniae being 35% of all E. coli
and K. pneumoniae isolated. These data are similar to
those reported in the scientific literature: frequency of
sepsis due to gram negative bacteria (GNB) is increasing
worldwide and E. coli is the most frequent GNB found
in septic patients admitted from the community [33–
36]. The rate of ESBL production among Enterobacteria-
ceae varies from country to country but it is increasing
through all Europe, with Italy having one of the highest
prevalence [31]. We specifically identified that
hospitalization in the previous 90 days is a specific risk
factor for ESBL Enterobacteriaceae, showing the
Table 3 Logistic regression analysis to assess the relationship between MDR infection and demographic, epidemiological, clinical, and
laboratory variables. (518)
Variables Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Female 1.2 (0.8–1.9) 0.39 1.2 (0.7–2.0) 0.42
Age 1.0 (1.0–1.0) 0.62 1.0 (1.0–2.0) 0.93
Septic shock 2.1 (1.3–3.4) 0.002 2.2 (1.3–3.7) 0.002
Antibiotic therapy in the past 90 days 1.7 (1.1–3.3) 0.03 1.0 (0.5–2.0) 1.0
Hospitalization in the past 90 days 3.2 (2.0–5.1) < 0.0001 2.3 (1.3–4.1) 0.003
Indwelling bladder catheter 2.2 (1.3–4.0) 0.006 1.9 (0.9–3.9) 0.11
Home wound care/infusion therapy 2.1 (1.2–3.6) 0.01 1.4 (0.7–2.8) 0.39
Chronic heart failure 2.1 (1.1–4.0) 0.03 1.7 (0.8–3.6) 0.14
Peripheral vascular disease 0.8 (0.3–2.4) 0.70
Stroke 2.0 (1.2–3.5) 0.01 1.8 (0.9–3.3) 0.08
Dementia 1.9 (1.1–3.3) 0.03 1.6 (0.8–3.0) 0.17
Haematological malignancy 2.2 (1.1–4.3) 0.03 1.6 (0.7–3.6) 0.28
Chronic steroid therapy 2.1 (1.2–3.9) 0.01 1.6 (0.8–3.2) 0.19
Table 4 Logistic regression analysis to assess the relationship between ESBL infection and demographic, epidemiological, clinical,
and laboratory variables. (518)
Variables Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Female 1.0 (0.5–1.8) 0.94 1.0 (0.5–1.8) 0.87
Age 1.0 (1.0–1.1) 0.10 1.0 (1.0–1.0) 0.50
Hospitalization in the past 90 days 2.4 (1.3–4.3) 0.004 2.1 (1.2–3.9) 0.02
Indwelling bladder catheter 2.5 (1.3–5.1) 0.008 2.0 (0.9–4.1) 0.08
Chronic heart failure 2.3 (1.0–5.0) 0.04 1.8 (0.8–4.1) 0.18
Stroke 2.5 (1.3–4.9) 0.006 2.1 (1.0–4.1) 0.04
Dementia 2.4 (1.2–4.7) 0.01 2.0 (1.0–4.0) 0.06
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Table 5 Study population according to in-hospital mortality. (518)
Variable Survivors Death p
Hospital mortality, n (%) 378 (74.0) 133 (25.7) –
Demographics characteristics
Female, n (%) 158 (41.8) 59 (44.4) 0.61
Median (IQR) age 78 (69–85) 81 (75–87) 0.01
Comorbidities, n (%)
COPD 85 (22.5) 28 (21.1) 0.73
Diabetes mellitus 99 (26.2) 23 (17.3) 0.04
Hypertension 211 (55.8) 75 (56.4) 0.91
Ischemic heart disease 73 (19.3) 36 (27.1) 0.06
Chronic heart failure 35 (9.3) 15 (11.3) 0.50
Peripheral vascular disease 14 (3.7) 14 (10.5) 0.003
Stroke 54 (14.3) 27 (20.3) 0.10
Hemiplegia 14 (3.7) 7 (5.3) 0.44
Dementia 54 (14.3) 24 (18.1) 0.30
Chronic liver disease 27 (7.1) 11 (8.3) 0.67
Cirrhosis 16 (4.2) 8 (6.0) 0.40
Chronic renal failure 64 (16.9) 31 (23.3) 0.10
Active dialysis 12 (3.2) 4 (3.0) 1.0
Solid cancer 53 (14.0) 20 (15.0) 0.77
Haematological malignancy 28 (7.4) 16 (12.0) 0.10
AIDS 2 (0.5) 1 (0.8) 1.0
Chemotherapy 19 (5.0) 9 (6.8) 0.45
Severe immunosuppression 62 (16.4) 34 (25.6) 0.02
Mild/moderate immunosuppression 61 (16.1) 22 (16.5) 0.91
Chronic steroid therapy 46 (12.2) 22 (16.5) 0.20
Median (IQR) Charlson comorbidity index 6 (4–8) 7 (5–9) 0.001
Risk factors, n (%)
LTCF 27 (7.1) 18 (13.5) 0.03
Antibiotic therapy in the past 90 days 50 (13.3) 30 (22.9) 0.009
Hospitalization in the past 90 days 91 (24.1) 55 (41.4) < 0.0001
Home wound care/infusion therapy 56 (14.8) 25 (18.8) 0.28
Day hospital attendance 73 (19.3) 25 (18.8) 0.90
Indwelling bladder catheter 49 (12.9) 20 (15.0) 0.55
Indwelling intravascular catheters 24 (6.4) 7 (5.3) 0.65
Clinical findings
Median (IQR) body temperature, °C 38.0 (37.2–38.8) 37.6 (36.6–38.5) 0.03
Median (IQR) systolic blood pressure, mmHg 113 (90–140) 99 (80–120) 0.0001
Median (IQR) diastolic blood pressure, mmHg 60 (50–73) 55 (46–68) 0.0006
Median (IQR) mean blood pressure, mmHg 78 (63–93) 70 (60–83) 0.0001
Median (IQR) heart rate, bpm 102 (87–120) 103 (88–120) 0.99
Median (IQR) oxygen saturation, % 95 (92–98) 94 (90–97) 0.06
Median (IQR) respiratory rate, bpm 22 (18–28) 28 (18–35) 0.008
Median (IQR) shock index 0.9 (0.7–1.2) 1.0 (0.8–1.3) 0.002
Laboratory findings
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Table 5 Study population according to in-hospital mortality. (518) (Continued)
Variable Survivors Death p
Median (IQR) arterial pH 7.5 (7.4–7.5) 7.4 (7.4–7.5) 0.0004
Median (IQR) PaCO2, mmHg 30.0 (26.0–35.0) 31.0 (24.0–36.5-) 0.80
Median (IQR) PaO2, mmHg 65 (55–76) 67 (55–82) 0.27
Median (IQR) HCO3- mEq/L 22.0 (18.3–25.0) 20.7 (15.4–24.0) 0.009
Median (IQR) PaO2/FiO2 ratio 281.0 (233.0–333.0) 271.5 (222.0–335.5) 0.88
Median (IQR) lactate, mEq/L 2.8 (2.1–4.0) 3.1 (2.1–5.7) 0.02
Median (IQR) white blood cells, cell/L−1 12.2 (7.4–17.8) 12.5 (7.3–19.3) 0.50
Median (IQR) platelet, cell/L− 1 198.0 (140.0–254.0) 181.0 (105.5–276.0) 0.45
Mean (SD) haemoglobin, g/dL 12.6 (2.2) 11.4 (2.3) < 0.0001
Median (IQR) glucose, mg/dL 144.5 (113.0–198.0) 126.5 (100.5–185.0) 0.004
Median (IQR) urea, mg/dL 58 (43–87) 87 (63–145) < 0.0001
Median (IQR) creatinine, mg/dL 1.5 (1.1–2.1) 2.0 (1.5–4.1) < 0.0001
Median (IQR) C-reactive protein, g/dL 10.0 (3.8–21.6) 15.7 (7.1–25.9) 0.0006
Median (IQR) Aspartate aminotransferase 28 (20–46) 33 (20–65) 0.05
Median (IQR) Alanine aminotransferase 21 (13–40) 24 (12–39) 0.85
Median (IQR) total bilirubin, mg/dL 0.8 (0.5–1.7) 1.0 (0.6–1.6) 0.52
Median (IQR) INR 1.3 (1.1–1.5) 1.3 (1.2–1.7) 0.40
Site of infection, n (%)
Lung 192 (57.3) 77 (67.0) 0.07
Urinary tract 134 (40.0) 31 (27.0) 0.01
Central nervous system 6 (1.8) 2 (1.7) 1.0
Abdomen 43 (12.8) 16 (13.9) 0.77
Skin and soft tissue) 18 (5.4) 13 (11.3) 0.03
Bone and joints 3 (0.9) 1 (0.9) 1.0
Multiple origin 58 (15.3) 24 (18.1) 0.47
Unknown origin 43 (11.4) 18 (13.5) 0.51
Severity of disease, n (%)
Hemodynamic failure 136 (36.3) 64 (48.9) 0.01
Respiratory failure 71 (19.0) 23 (17.6) 0.71
Renal failure) 153 (41.1) 68 (51.5) 0.04
Liver failure 44 (12.6) 23 (18.1) 0.12
Cognitive impairment 106 (29.9) 49 (40.8) 0.03
Haematological dysfunction 34 (9.0) 15 (11.5) 0.42
Coagulation dysfunction 33 (9.9) 22 (18.0) 0.02
Metabolic dysfunction 261 (74.8) 94 (78.3) 0.43
Shock 75 (19.8) 69 (51.9) < 0.0001
Microbiological findings, n (%)
Blood cultures performed in the first 48 h 326 (86.2) 114 (85.7) 0.88
Bacteremia 148 (45.4) 48 (42.1) 0.54
Cultures () ()
Culture positive 224 (59.3) 77 (57.9) 0.78
Polymicrobial infection 16 (7.1) 13 (16.7) 0.01
MDR pathogen isolated 52 (13.8) 35 (26.3) 0.001
ESBL producer pathogen isolated 33 (8.7) 16 (12.0) 0.27
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important role played by the contact with health care
setting, and suggesting the necessity of administering
carbapenems empirically in septic patients with this risk
factor. The other risk factor associated with ESBL+ bac-
teria is a positive history of stroke which could be ex-
plained in light of the prolonged hospitalization, nursing
home residency or use of indwelling invasive devices
(e.g., nasogastric tube, gastrostomy tube, bladder cath-
eter). Considering the prevalence of ESBL Enterobacteri-
aceae and in case a MDRO infection is suspected (e.g.,
previous hospitalization), an empiric antibiotic therapy
including carbapenems for ESBL+ pathogens could be
considered, while waiting for culture results.
Sepsis due to MDRO is associated with higher mortality
rates and the isolation of a MDRO is an independent risk
factor for mortality. We know that patients presenting
with MDRO infection have often a high number of co-
morbidities and a longer medical history, but also that
MDRO infection and an inappropriate empirical antibiotic
therapy are greatly correlated one to the other [5, 6]. In
some studies MDRO infection is an independent risk
factor for mortality, whereas in others it is a risk factor for
inappropriate antibiotic therapy being the last an inde-
pendent risk factor for mortality [5, 15].
Our study has some limitations, including the retrospect-
ive nature and the single-center design. Our primary
Table 6 Logistic regression analysis to assess the relationship between hospital mortality and demographic, epidemiological, clinical,
and laboratory variables. (518)
Variables Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Female 1.1 (0.7–1.7) 0.61 1.1 (0.5–2.3) 0.79
Age 1.0 (1.0–1.0) 0.01 1.0 (1.0–1.1) 0.053
Septic shock 4.4 (2.9–6.7) < 0.0001 3.2 (1.5–7.0) 0.003
Nursing home 2.0 (1.1–3.8) 0.03 0.4 (0.1–1.4) 0.14
Antibiotic therapy in the past 90 days 1.9 (1.2–3.2) 0.01 1.1 (0.4–3.0) 0.90
Hospitalization in the past 90 days 2.2 (1.5–3.4) < 0.0001 1.1 (0.4–2.7) 0.85
Diabetes mellitus 0.6 (0.4–1.0) 0.04 0.8 (0.3–2.1) 0.71
Peripheral vascular disease 3.1 (1.4–6.6) 0.004 1.4 (0.3–5.9) 0.67
Severe immunosoppression 1.8 (1.1–2.8) 0.02 1.9 (0.8–4.9) 0.17
Lung site 1.5 (1.0–2.4) 0.07 1.7 (0.7–4.0) 0.21
Urinary tract site 0.6 (0.4–0.9) 0.01 0.6 (0.3–1.5) 0.27
Skin and soft tissue site 2.2 (1.1–4.7) 0.03 3.2 (0.9–11.4) 0.07
Renal failure 1.5 (1.0–2.3) 0.04 1.5 (0.7–3.1) 0.26
Cognitive impairment 1.6 (1.1–2.5) 0.03 1.5 (0.7–3.0) 0.30
Coagulation dysfunction 2.0 (1.1–3.6) 0.02 3.2 (1.1–8.8) 0.03
SOFA 1.3 (1.2–1.4) < 0.0001
Quick SOFA 1.5 (1.1–2.1) 0.008
MDR pathogen isolated 2.2 (1.4–3.6) 0.001 4.6 (2.0–10.6) < 0.001
Use of vasopressors 2.4 (1.5–3.9) < 0.0001
Polymicrobial infection 2.6 (1.2–5.7) 0.02 2.4 (0.7–7.7) 0.15
Table 5 Study population according to in-hospital mortality. (518) (Continued)
Variable Survivors Death p
MRSA isolated 6 (1.6) 14 (10.5) < 0.0001
Appropriate empiric antibiotic therapy according to local guidelines 190 (56.6) 77 (61.6) 0.33
Appropriate empiric antibiotic therapy according to antibiotic
susceptibility of the isolated pathogen
118 (71,1%) 56 (37,1%) 0,058
Use of vasopressors 49 (13.0) 35 (26.3) < 0.0001
Mechanical ventilation 4 (1.6) 4 (5.3) 0.09
n number, IQR interquartile range, COPD chronic obstructive pulmonary disease, AIDS Acquired immune deficiency syndrome, LTCF long term care facility, INR
International normalized ratio, MOF multi organ failure (other than primary site of infection)
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outcome was mortality due to all causes during
hospitalization, while sepsis-related mortality and long
term outcomes would have been additional and interesting
primary outcomes. Finally, we found 41.7% of population
who received an empiric antibiotic therapy not concordant
with local guidelines. Our local guidelines suggest broad
antimicrobial spectrum antibiotics in patients with a suspi-
cion of MDRO infection according to a list of risk factors
recorded from previously published literature. So far, no
specific risk factors for single MDRO in septic patients
were identified. For the first time, we showed
hospitalization in the previous 90 days and stroke as inde-
pendently associated with ESBL+ bacterial infection in
sepsis. Finally, our results should be interpreted with cau-
tion and not be widely generalized, as different causative
pathogens of sepsis, different rates of antibiotic resistances,
as well as risk factors related to different healthcare organi-
zations might be recognized worldwide.
The strength and novelty of our study lie on a specific
analysis of all risk factors for MDRO in a large sample of
consecutive patients coming from the community and
admitted to the ED, during a 5-year period, with the
diagnosis of sepsis according to Sepsis-3 definition [4].
Several studies evaluated risk factors for MDRO in ei-
ther bacteremic patients or in those affected by single
organ disease (e.g., pneumonia). Our study is the first
one evaluating all risk factors for MDRO previously pub-
lished in literature in patients with sepsis regardless the
site of infection.
Conclusion
In conclusion, our finding of an isolation of a MDRO in
17% of patients with sepsis coming from the community
advocates for a better recognition of possible risk factors
for MDRO and especially for ESBL+ Enterobacteriaceae.
Patients with sepsis who have been hospitalized in the pre-
vious 90 days and/or with a history of stroke might be
ideal candidate for a broader empiric antibiotic therapy
covering ESBL+ Enterobacteriaceae, while waiting for
microbiological results.
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